SavePeptides
SavePeptidesCompound
Re-checked hourly
All peptides
GrowthFDA-approvedVendors pending
FDA-approvedVendors pendingFacts verified · 2026-05-25

Sermorelin

Also known as grf(1–29) amide, ghrh(1–29) amide · Wikipedia

Sermorelin is the synthetic acetate salt of GRF(1-29) amide, the shortest fully active fragment of native human growth hormone-releasing hormone (GHRH). It was originally approved by the FDA as Geref (Serono) for pediatric growth hormone deficiency and as a diagnostic agent; Geref was withdrawn from the US market in 2008 for commercial reasons rather than safety. Sermorelin acts on pituitary somatotrophs to stimulate physiologic, pulsatile growth-hormone release while preserving hypothalamic feedback. Modern compounded use focuses on adult GH axis support and age-related GH decline. Largely supplanted in research by longer-acting GHRH analogs such as CJC-1295 and tesamorelin. Also known as: GRF(1-29) amide; GHRH(1-29) amide.

—

best

price

—

per

mg

—

vendors

tracked

FDA-approved

stage

Vendor data

Coming soon.

Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.

Browse all vendors

Mechanism of action

Sermorelin is the synthetic acetate of GHRH(1-29) amide, the minimal fully active N-terminal fragment of native human growth hormone-releasing hormone [Prakash 1999 Drugs review, PMID 18031173]. It binds the pituitary GHRH receptor (GHRHR), a class B GPCR on somatotrophs, raising intracellular cAMP and triggering Ca2+-dependent release of stored growth hormone.

Sermorelin is the synthetic acetate of GHRH(1-29) amide, the minimal fully active N-terminal fragment of native human growth hormone-releasing hormone [Prakash 1999 Drugs review, PMID 18031173]. It binds the pituitary GHRH receptor (GHRHR), a class B GPCR on somatotrophs, raising intracellular cAMP and triggering Ca2+-dependent release of stored growth hormone. Because the molecule is unmodified GHRH (no DPP-IV-resistant substitutions or lipidation), it is cleaved at the Ala2-Asp3 bond within minutes, producing a short, clean, physiologic GH pulse that preserves negative feedback by somatostatin and IGF-1 [Thorner 1996 JCEM, PMID 8772599]. Pulsatile signalling is thought to better mimic native GH rhythm than exogenous recombinant hGH.

Pharmacokinetic properties

Half-life

~11-12 minutes subcutaneous or IV

Routes

subcutaneous

Bioavailability

Very short plasma half-life, but downstream GH/IGF-1 elevation persists for hours; typically dosed at bedtime to mirror natural GH pulse.

Amino-acid sequence

Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 (GHRH 1-29 amide)

Use & research dosing

GH ReleaseRecovery

Historically labeled (Geref) for pediatric short stature at 30 mcg/kg/day subcutaneously at bedtime and as an intravenous diagnostic at 1 mcg/kg. Modern US compounded use for adult GH-axis support (research framing only) is commonly 100-300 mcg subcutaneously at bedtime, 5-7 nights per week, in cycles of 3-6 months. Bedtime dosing is intended to align with the dominant nocturnal GH pulse. Some protocols co-administer a GHRP such as ipamorelin for synergistic GH release.

Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.

Editorial perspective

The original GHRH analog in clinical use, sermorelin remains a useful diagnostic probe of pituitary GH reserve. Geref Diagnostic and Geref pediatric formulations (Serono/EMD Serono) were withdrawn from the US market in 2008 for commercial (supply) reasons rather than safety findings. Compounded sermorelin is widely prescribed by US anti-aging and longevity clinics, although the very short plasma half-life (~11-12 minutes) has driven research interest toward longer-acting GHRH analogs such as CJC-1295 with DAC and tesamorelin.

— SavePeptides editorial desk · last updated 2026-05-25

Cautions & contraindications

Before researching this compound, note:

  • Geref (FDA-approved formulation) was withdrawn from US market in 2008 for commercial reasons; current US supply is via compounding pharmacies only
  • avoid in active or suspected malignancy (GH/IGF-1 axis activation)
  • avoid in pregnancy and breastfeeding
  • blunted response with concurrent glucocorticoids
  • avoid in patients with structural pituitary disease or disrupted hypothalamic-pituitary axis
  • hypothyroidism can blunt the GH response and should be corrected first
  • injection site reactions, flushing, and headache reported
  • should not be used with somatostatin analogs (octreotide, lanreotide) which suppress GH release
  • hyperglycemia and reduced insulin sensitivity possible with chronic use

Research foundation

The papers behind the page.

  1. [01]https://pubmed.ncbi.nlm.nih.gov/18031173/
  2. [02]https://pubmed.ncbi.nlm.nih.gov/8772599/
  3. [03]https://pubmed.ncbi.nlm.nih.gov/2879138/

Facts verified

2026-05-25

Confidence

medium

What this means

  • Geref withdrawn 2008; current US availability is compounded only — strictly speaking no FDA-marketed sermorelin product exists today

How we check →

Vendor data coming soon

All vendors

001 — Independent

We don't list what we wouldn't research.

SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.

002 — Vendor-funded

Free to browse. Supported by referrals.

SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.

003 — Research use

Research-use disclaimer.

SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.